Forge Biologics to Present and Participate at Upcoming Investor Conferences
Ohio Pen/10194062

COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that company leadership members will be making presentations and taking one-on-one meetings at three upcoming investor relations conferences.

Jefferies Cell & Genetic Medicine Summit
Friday, September 30, 10:00-10:25 a.m. ET
Presenter: Christina Perry, Senior Vice President and Head, Finance & Investor Relations
Webcast Link: https://wsw.com/webcast/jeff259/forge/2001825

Chardan Genetic Medicines Conference
Monday, October 3, 2:00-2:25 p.m. ET
Presenter: Timothy J. Miller, CEO, President and Co-Founder
Webcast Link: https://wsw.com/webcast/chard14/forge/2063205

More on Ohio Pen

• Parkchester Oral & Maxillofacial Surgery Celebrates 450+ 5-Star Reviews
• The AI CEO Partners with D3 Hockey News to Elevate the Voice of Division III Hockey Nationwide
• Statement from the Campaign of Theodis Daniel, Republican for U.S. Congress (TX-18)
• Divine Punk Announces Happy Christmas, a Holiday Soundscape by Rebecca Noelle
• $430 Million 2026 Revenue Forecast; 26% Organic Growth; $500,000 Stock Dividend Highlight a Powerful AI & Digital Transformation Story: IQSTEL $IQST

SVB Securities Biopharma Private Company Connect
Wednesday, October 26, 2022
Company executives will hold virtual one-on-one meetings with investors during the event. Meetings with the management team may be requested through SVB Securities.

Forge's presentations will be available for 90 days following each event by visiting the Company's Events website at https://www.forgebiologics.com/news/#events.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge's mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge's 200,000 square foot facility utilizes 20 cGMP suites in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility focused on AAV manufacturing and can host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.

More on Ohio Pen

• Wzzph Deploys 5-Million-TPS Trading Engine with Hot-Cold Wallet Architecture Serving 500,000 Active Users Across Latin America
• Preston Dermatology & Skin Surgery Center and Dr. Sheel Desai Solomon Dominate Raleigh's Best Awards from The News & Observer
• $73.6 Million Multi-Year Backlog and Florida State Term Contract Drive Momentum for AI-Cybersecurity Pioneer: Cycurion, Inc. (N A S D A Q: CYCU) $CYCU
• Year-Round Deals for Customers With Square Signs
• SecurePII Raises US$3.5M (A$5M) to Unlock AI and Compliance for Voice Data and Expands Global Presence

Contacts

Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications
media@forgebiologics.com

Investor Relations
Christina Perry
Senior Vice President, Head of Finance and Investor Relations
Investors@forgebiologics.com

---

Show All News | Report Violation